SK Biopharmaceuticals (326030) Investor presentation summary

Financial performance and growth trajectory

• Achieved record operating profit of KRW 89.8B in Q1 2026, with XCOPRIⓇ sales reaching KRW 197.7B ($135M), up 15.8% QoQ and 48.4% YoY.

• Net profit for Q1 2026 was KRW 102.7B, reflecting a 423.5% YoY increase.

• Revenue for Q1 2026 rose to KRW 227.9B, a 17.2% QoQ and 57.8% YoY increase.

• XCOPRIⓇ US annual sales have shown consistent growth, reaching $443.2M in FY2025.

• FY guidance for XCOPRIⓇ revenue maintained at $550-580M.

Product portfolio and pipeline expansion

• XCOPRIⓇ (cenobamate) is positioned as a best-in-class epilepsy treatment, with global expansion through direct sales and licensing.

• Indication and age expansion for XCOPRIⓇ expected to drive sales to $1B by 2029.

• NDA for cenobamate oral suspension submitted in March 2026; sNDA filings for PGTC and pediatric use planned within 2026.

• Early-stage pipeline includes CNS, oncology, and new modalities such as radiopharmaceutical therapy (RPT) and targeted protein degradation (TPD).

• Joint venture in China (Ignis Therapeutics) launched cenobamate in March 2026, with further market opportunities anticipated.

Strategic investments and R&D focus

• Reinvesting XCOPRIⓇ cash flow into asset acquisition and R&D diversification to fuel next-generation growth.

• Transitioning from asset-based to platform-based R&D, with a focus on sustainable pipeline development.

• Recent in-licensing of SKL35501 and SKL37321, and collaborations for RPT and TPD platforms.

• Strengthening clinical capabilities through parallel development of in-house and licensed-in pipelines.

• Establishing a sustainable RPT value chain and securing radioisotope supply agreements.